Aaron G.L. Fletcher - Mar 31, 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Aaron Fletcher by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Mar 31, 2022
Transactions value $
$3,498,600
Form type
4
Date filed
4/4/2022, 05:28 PM
Previous filing
Feb 1, 2022
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Purchase $3.5M +735K $4.76 735K Mar 31, 2022 See footnote F1
holding CUE Common Stock 165K Mar 31, 2022 Direct
holding CUE Common Stock 8.87K Mar 31, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP.